Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

Marina Bolzoni, Paola Storti, Sabrina Bonomini, Katia Todoerti, Daniela Guasco, Denise Toscani, Luca Agnelli, Antonino Neri, Vittorio Rizzoli, Nicola Giuliani

Research output: Contribution to journalArticle

Abstract

Multiple myeloma (MM)-induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-κB ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells. The purpose of the study was to investigate the effect of the immunomodulatory drugs on RANKL/OPG ratio, the production of pro-osteoclastogenic cytokines, and MM-induced OC formation. We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells. A reduction in CD49d expression, a molecule critically involved in RANKL upregulation in the MM microenvironment, accompanied this effect. Consistently, the pro-osteoclastogenic property of MM cells co-cultured with PreOBs was reduced by both LEN and POM. We further investigated the effect of these drugs on the transcriptional profile of both MM cells and PreOBs by microarray analysis, which showed that adhesion molecules, such as ITGA8 and ICAM2, are significantly downregulated in MM cells. Our data suggest that LEN and POM inhibit MM-induced OC formation through normalization of the RANKL/OPG ratio targeting the expression of adhesion molecules by MM cells.

Original languageEnglish
Pages (from-to)387-397
Number of pages11
JournalExperimental Hematology
Volume41
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Osteoprotegerin
Osteoclasts
Multiple Myeloma
Pharmaceutical Preparations
lenalidomide
pomalidomide
Up-Regulation
Tissue Array Analysis
RANK Ligand
Cultured Cells
Down-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. / Bolzoni, Marina; Storti, Paola; Bonomini, Sabrina; Todoerti, Katia; Guasco, Daniela; Toscani, Denise; Agnelli, Luca; Neri, Antonino; Rizzoli, Vittorio; Giuliani, Nicola.

In: Experimental Hematology, Vol. 41, No. 4, 04.2013, p. 387-397.

Research output: Contribution to journalArticle

Bolzoni, Marina ; Storti, Paola ; Bonomini, Sabrina ; Todoerti, Katia ; Guasco, Daniela ; Toscani, Denise ; Agnelli, Luca ; Neri, Antonino ; Rizzoli, Vittorio ; Giuliani, Nicola. / Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. In: Experimental Hematology. 2013 ; Vol. 41, No. 4. pp. 387-397.
@article{11f312286ab848e684f9aad986c8df56,
title = "Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules",
abstract = "Multiple myeloma (MM)-induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-κB ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells. The purpose of the study was to investigate the effect of the immunomodulatory drugs on RANKL/OPG ratio, the production of pro-osteoclastogenic cytokines, and MM-induced OC formation. We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells. A reduction in CD49d expression, a molecule critically involved in RANKL upregulation in the MM microenvironment, accompanied this effect. Consistently, the pro-osteoclastogenic property of MM cells co-cultured with PreOBs was reduced by both LEN and POM. We further investigated the effect of these drugs on the transcriptional profile of both MM cells and PreOBs by microarray analysis, which showed that adhesion molecules, such as ITGA8 and ICAM2, are significantly downregulated in MM cells. Our data suggest that LEN and POM inhibit MM-induced OC formation through normalization of the RANKL/OPG ratio targeting the expression of adhesion molecules by MM cells.",
author = "Marina Bolzoni and Paola Storti and Sabrina Bonomini and Katia Todoerti and Daniela Guasco and Denise Toscani and Luca Agnelli and Antonino Neri and Vittorio Rizzoli and Nicola Giuliani",
year = "2013",
month = "4",
doi = "10.1016/j.exphem.2012.11.005",
language = "English",
volume = "41",
pages = "387--397",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

AU - Bolzoni, Marina

AU - Storti, Paola

AU - Bonomini, Sabrina

AU - Todoerti, Katia

AU - Guasco, Daniela

AU - Toscani, Denise

AU - Agnelli, Luca

AU - Neri, Antonino

AU - Rizzoli, Vittorio

AU - Giuliani, Nicola

PY - 2013/4

Y1 - 2013/4

N2 - Multiple myeloma (MM)-induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-κB ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells. The purpose of the study was to investigate the effect of the immunomodulatory drugs on RANKL/OPG ratio, the production of pro-osteoclastogenic cytokines, and MM-induced OC formation. We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells. A reduction in CD49d expression, a molecule critically involved in RANKL upregulation in the MM microenvironment, accompanied this effect. Consistently, the pro-osteoclastogenic property of MM cells co-cultured with PreOBs was reduced by both LEN and POM. We further investigated the effect of these drugs on the transcriptional profile of both MM cells and PreOBs by microarray analysis, which showed that adhesion molecules, such as ITGA8 and ICAM2, are significantly downregulated in MM cells. Our data suggest that LEN and POM inhibit MM-induced OC formation through normalization of the RANKL/OPG ratio targeting the expression of adhesion molecules by MM cells.

AB - Multiple myeloma (MM)-induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-κB ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells. The purpose of the study was to investigate the effect of the immunomodulatory drugs on RANKL/OPG ratio, the production of pro-osteoclastogenic cytokines, and MM-induced OC formation. We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells. A reduction in CD49d expression, a molecule critically involved in RANKL upregulation in the MM microenvironment, accompanied this effect. Consistently, the pro-osteoclastogenic property of MM cells co-cultured with PreOBs was reduced by both LEN and POM. We further investigated the effect of these drugs on the transcriptional profile of both MM cells and PreOBs by microarray analysis, which showed that adhesion molecules, such as ITGA8 and ICAM2, are significantly downregulated in MM cells. Our data suggest that LEN and POM inhibit MM-induced OC formation through normalization of the RANKL/OPG ratio targeting the expression of adhesion molecules by MM cells.

UR - http://www.scopus.com/inward/record.url?scp=84876158316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876158316&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2012.11.005

DO - 10.1016/j.exphem.2012.11.005

M3 - Article

C2 - 23178378

AN - SCOPUS:84876158316

VL - 41

SP - 387

EP - 397

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 4

ER -